{
    "hands_on_practices": [
        {
            "introduction": "Understanding the hereditary nature of retinoblastoma is a cornerstone of pediatric oncology and genetic counseling. This first exercise focuses on quantifying the risk for an individual child when a parent carries a germline $RB1$ mutation. By combining the principles of Mendelian inheritance with the clinical concept of penetrance, you will calculate the actual probability of disease manifestation, a critical skill for advising affected families. ",
            "id": "4723449",
            "problem": "A patient carries a germline mutation in the Retinoblastoma 1 (RB1) gene and is heterozygous at the RB1 locus. In classical Mendelian segregation for an autosomal locus, each child of a heterozygous parent has a probability of $0.5$ to inherit the mutant allele. Clinical penetrance is defined as the conditional probability that an individual expressing the genotype will manifest the phenotype. For retinoblastoma in germline RB1 mutation carriers, assume penetrance $p = 0.9$. Assume there are no de novo mutations, no germline mosaicism, and that the other parent is unaffected. Using only these premises and probability laws, compute the overall probability that a child of this carrier will develop retinoblastoma. Express your answer as a decimal and round to four significant figures.",
            "solution": "The problem asks for the overall probability that a child of a carrier of a germline Retinoblastoma 1 ($RB1$) gene mutation will develop retinoblastoma. The problem statement is first validated for correctness and solvability.\n\n### Step 1: Extract Givens\n-   The parent is heterozygous at the $RB1$ locus, carrying one mutant allele and one wild-type allele.\n-   The probability of a child inheriting the mutant allele from this heterozygous parent is $0.5$.\n-   The clinical penetrance, $p$, for germline $RB1$ mutation carriers is $p = 0.9$. Penetrance is defined as the conditional probability that an individual with the predisposing genotype (in this case, carrying the germline mutation) will manifest the phenotype (develop retinoblastoma).\n-   The other parent is unaffected and, by implication, homozygous for the wild-type allele at the $RB1$ locus.\n-   There are no *de novo* mutations.\n-   There is no germline mosaicism.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, drawing upon established principles of Mendelian genetics and the epidemiology of hereditary retinoblastoma. The concepts of heterozygosity, autosomal inheritance, and penetrance are well-defined. The provided numerical values ($0.5$ for allele transmission and $0.9$ for penetrance) are standard and realistic for this condition. The problem is well-posed, self-contained, and objective. It provides all necessary information and constraints (e.g., \"no de novo mutations\") to permit a unique and meaningful solution. Therefore, the problem is deemed valid.\n\n### Step 3: Derivation of the Solution\nWe can solve this problem using the law of total probability. Let us define the relevant events:\n-   Let $M$ be the event that the child inherits the mutant $RB1$ allele from the heterozygous parent.\n-   Let $M^c$ be the complementary event that the child inherits the wild-type allele from the heterozygous parent.\n-   Let $D$ be the event that the child develops retinoblastoma.\n\nFrom the problem statement, we are given the probability of inheriting the mutant allele:\n$$P(M) = 0.5$$\nSince $M$ and $M^c$ are mutually exclusive and exhaustive events, the probability of inheriting the wild-type allele is:\n$$P(M^c) = 1 - P(M) = 1 - 0.5 = 0.5$$\n\nWe are also given the penetrance, which is the conditional probability of developing retinoblastoma given that the child has inherited the mutant allele. This is expressed as:\n$$P(D|M) = p = 0.9$$\n\nNext, we must consider the probability of developing retinoblastoma if the child does *not* inherit the mutant allele, which is the event $M^c$. In this case, the child receives a wild-type allele from the carrier parent. The problem states that the other parent is unaffected, which implies they are homozygous for the wild-type allele and can only contribute a wild-type allele. Therefore, a child in the $M^c$ scenario has a genotype that is homozygous for the wild-type allele. The problem also specifies that there are no *de novo* mutations. Consequently, without a mutant allele, the child cannot develop the hereditary form of retinoblastoma. The probability of developing the disease in this case is zero.\n$$P(D|M^c) = 0$$\n\nThe law of total probability states that the total probability of an event $D$ can be found by summing the probabilities of $D$ conditioned on a set of mutually exclusive and exhaustive events. Here, the events are $M$ and $M^c$.\n$$P(D) = P(D|M)P(M) + P(D|M^c)P(M^c)$$\n\nSubstituting the values we have established:\n$$P(D) = (0.9) \\times (0.5) + (0) \\times (0.5)$$\n$$P(D) = 0.45 + 0$$\n$$P(D) = 0.45$$\n\nThe problem requires the answer to be expressed as a decimal rounded to four significant figures. The calculated probability is $0.45$. To express this with four significant figures, we write it as $0.4500$.",
            "answer": "$$\\boxed{0.4500}$$"
        },
        {
            "introduction": "Effective management of retinoblastoma requires a sophisticated, multi-modal approach tailored to the individual patient. This practice simulates a clinical decision-making process, challenging you to act as part of a virtual tumor board. You will synthesize diagnostic information, including the International Intraocular Retinoblastoma Classification (IIRC), patient age, and tumor location, to select the most appropriate treatment plan from several options, balancing eye salvage with long-term safety. ",
            "id": "5199660",
            "problem": "A pediatric oncology team is designing a principled decision algorithm for retinoblastoma management that maps International Intraocular Retinoblastoma Classification (IIRC) grouping and seed status to preferred therapy. The algorithm must incorporate constraints of age-dependent feasibility of intra-arterial delivery, lens clarity for optical access, and spatial risk relative to the fovea and optic disc for focal therapies. The algorithm should prioritize eye salvage and visual function while minimizing long-term harms such as radiation-induced secondary malignancies.\n\nFundamental base:\n- The International Intraocular Retinoblastoma Classification (IIRC) defines intraocular disease severity by tumor size/location and the presence and pattern of vitreous or subretinal seeds: groups A and B are limited disease without seeding; group C includes focal vitreous or subretinal seeding; group D includes diffuse vitreous or subretinal seeding; group E includes extensive disease with poor salvage potential.\n- Vitreous seeds are avascular tumor deposits that respond poorly to systemic chemotherapy due to limited drug penetration but respond to intravitreal chemotherapy; subretinal seeds are hypoxic deposits that respond to chemoreduction when coupled with focal consolidation.\n- External Beam Radiation Therapy (EBRT) confers a high risk of radiation-induced secondary malignancies in children with germline retinoblastoma and is generally avoided when effective alternatives exist.\n- Intra-arterial chemotherapy (IAC) feasibility increases with age as the caliber of the ophthalmic artery becomes suitable; many centers use IAC reliably from approximately $6$ to $12$ months of age and beyond. Intravitreal chemotherapy is effective for vitreous seeds when applied with safety protocols.\n- Plaque brachytherapy and transpupillary laser photocoagulation impose spatial constraints to avoid radiation maculopathy and optic neuropathy; plaques are generally reserved for lesions at least approximately $3$ $\\mathrm{mm}$ away from the fovea and optic disc, with appropriate size and thickness; cryotherapy is best for anterior peripheral lesions anterior to the equator. Clear lens media are required for laser-based therapies to target posterior lesions.\n- Consolidative focal therapies are selected based on tumor location relative to the fovea and optic disc to preserve central vision.\n\nClinical scenario:\nA child aged $12$ months with confirmed germline Retinoblastoma $1$ (RB1) pathogenic variant presents with bilateral retinoblastoma. The right eye is IIRC group D with diffuse vitreous seeding and a posterior tumor whose edge lies $2.5$ $\\mathrm{mm}$ from the foveal center and $4$ $\\mathrm{mm}$ from the optic disc; the lens is clear. The left eye is IIRC group C with a solitary peripheral tumor anterior to the equator, $10$ $\\mathrm{mm}$ from the foveal center and $12$ $\\mathrm{mm}$ from the optic disc, thickness $3$ $\\mathrm{mm}$, with focal subretinal seeding contiguous with the main lesion; the lens is clear. There is no evidence of extraocular extension. The family desires eye salvage and avoidance of long-term radiation risks if effective alternatives exist.\n\nWhich composite management plan most closely aligns with a principled algorithm that maps IIRC grouping and seed status to preferred therapy, incorporating age feasibility for intra-arterial chemotherapy, lens clarity requirements for focal therapies, and safe spatial constraints relative to the fovea and optic disc?\n\nA. Systemic chemoreduction for both eyes, intravitreal melphalan for the right eye seeds, and laser photocoagulation for the left eye lesion.\n\nB. Intra-arterial chemotherapy to the right eye with adjunct intravitreal melphalan for vitreous seeds, and plaque brachytherapy to the left eye lesion; avoid External Beam Radiation Therapy.\n\nC. External Beam Radiation Therapy to both eyes due to posterior involvement and seeding, with deferred focal therapies to minimize immediate anesthesia exposures.\n\nD. Primary enucleation of the right eye given group D status, and plaque brachytherapy for the left eye lesion.\n\nE. Intravitreal melphalan alone to the right eye without intra-arterial or systemic chemotherapy, and cryotherapy to the left eye lesion without chemoreduction.",
            "solution": "The problem statement is validated as follows:\n**Step 1: Extract Givens**\n\n**Fundamental Principles:**\n*   **IIRC Groups:**\n    *   Groups A and B: Limited disease, no seeding.\n    *   Group C: Focal vitreous or subretinal seeding.\n    *   Group D: Diffuse vitreous or subretinal seeding.\n    *   Group E: Extensive disease, poor salvage potential.\n*   **Seed Behavior and Treatment:**\n    *   Vitreous seeds: Avascular, poor response to systemic chemotherapy, respond to intravitreal chemotherapy.\n    *   Subretinal seeds: Hypoxic, respond to chemoreduction plus focal consolidation.\n*   **Radiation Therapies:**\n    *   External Beam Radiation Therapy (EBRT): High risk of secondary malignancies in germline retinoblastoma; generally avoided.\n    *   Plaque brachytherapy: Reserved for lesions at least $\\approx 3$ $\\mathrm{mm}$ from the fovea/optic disc.\n*   **Chemotherapy Delivery:**\n    *   Intra-arterial chemotherapy (IAC): Feasible from $\\approx 6-12$ months of age.\n    *   Intravitreal chemotherapy (IViC): Effective for vitreous seeds.\n*   **Focal Therapies:**\n    *   Transpupillary laser photocoagulation (TTP): Requires clear lens media for posterior lesions; has spatial constraints.\n    *   Cryotherapy: Best for anterior peripheral lesions.\n*   **General Strategy:** Consolidative focal therapies are chosen based on tumor location to preserve central vision.\n\n**Clinical Scenario Data:**\n*   **Patient:** Age $12$ months.\n*   **Genetics:** Confirmed germline Retinoblastoma $1$ (RB1) pathogenic variant.\n*   **Presentation:** Bilateral retinoblastoma, no extraocular extension.\n*   **Family Goal:** Prioritize eye salvage and avoid long-term radiation risks.\n*   **Right Eye (RE):**\n    *   **IIRC Group:** D.\n    *   **Seeding:** Diffuse vitreous seeding.\n    *   **Tumor:** Posterior, edge $2.5$ $\\mathrm{mm}$ from foveal center and $4$ $\\mathrm{mm}$ from optic disc.\n    *   **Media:** Lens is clear.\n*   **Left Eye (LE):**\n    *   **IIRC Group:** C.\n    *   **Tumor:** Solitary, peripheral, anterior to the equator. Location is $10$ $\\mathrm{mm}$ from fovea, $12$ $\\mathrm{mm}$ from optic disc. Thickness is $3$ $\\mathrm{mm}$.\n    *   **Seeding:** Focal subretinal seeding, contiguous with the main lesion.\n    *   **Media:** Lens is clear.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using established concepts and terminology from pediatric ophthalmology and oncology (IIRC classification, RB1 genetics, IAC, IViC, etc.). It is well-posed, providing a specific, detailed clinical scenario and a set of principles to apply, leading to a deducible, optimal management plan. The language is objective and clinical. The data is internally consistent; for instance, the patient's age of $12$ months makes IAC a feasible option as per the provided principles, and the tumor characteristics align with the assigned IIRC groups. The scenario is clinically realistic. The problem requires a multi-step logical deduction based on the provided rules, making it a non-trivial reasoning task.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. A solution will be derived by applying the given principles to the patient data, followed by an evaluation of each option.\n\n**Derivation of the Principled Management Plan**\n\n**Analysis of the Right Eye (RE):**\nThe right eye is IIRC Group D with diffuse vitreous seeding and a posterior tumor. The goal is eye salvage.\n1.  **Main Tumor and IIRC Group D:** Group D is advanced disease. The principles state IAC is feasible for a $12$-month-old child. IAC delivers high-concentration chemotherapy directly to the eye, offering a higher success rate for salvaging Group D eyes compared to systemic chemotherapy, with fewer systemic side effects. This is the preferred modality for chemoreduction of the primary tumor.\n2.  **Seeding:** The eye has diffuse vitreous seeding. The principles state that vitreous seeds respond poorly to systemic chemotherapy but well to intravitreal chemotherapy. Therefore, adjunct intravitreal chemotherapy (e.g., intravitreal melphalan) is required to control the seeds.\n3.  **Focal Consolidation:** The tumor edge is $2.5$ $\\mathrm{mm}$ from the foveal center. The principles specify that plaque brachytherapy is for lesions at least $\\approx 3$ $\\mathrm{mm}$ away from the fovea. Thus, plaque brachytherapy is contraindicated due to the high risk of radiation maculopathy and severe vision loss.\n4.  **EBRT:** The principles and family's wishes strongly advise against EBRT in a child with a germline RB1 variant when effective alternatives exist. The combination of IAC and IViC is such an alternative.\n5.  **Conclusion for RE:** The optimal salvage strategy for the right eye is a combination of intra-arterial chemotherapy (IAC) for the main tumor and adjunct intravitreal chemotherapy (IViC) for the diffuse vitreous seeds.\n\n**Analysis of the Left Eye (LE):**\nThe left eye is IIRC Group C with a solitary, anterior peripheral tumor and focal subretinal seeding.\n1.  **Tumor and IIRC Group C:** Group C disease with subretinal seeds requires treatment. The principles state that subretinal seeds respond to \"chemoreduction when coupled with focal consolidation.\"\n2.  **Chemoreduction:** The eye requires some form of chemoreduction. This could be achieved via systemic chemotherapy or potentially by systemic spillover from the IAC administered to the right eye. Some Group C tumors can also be managed with primary focal therapy without prior chemoreduction.\n3.  **Focal Consolidation Therapy:** The tumor is $10$ $\\mathrm{mm}$ from the fovea and $12$ $\\mathrm{mm}$ from the optic disc, well outside the critical zones. Its thickness is $3$ $\\mathrm{mm}$.\n    *   **Plaque Brachytherapy:** The location and thickness ($3$ $\\mathrm{mm}$) make this tumor an ideal candidate for plaque brachytherapy. It is a highly effective focal radiation therapy that meets the spatial safety constraints.\n    *   **Cryotherapy:** The principles state cryotherapy is \"best for anterior peripheral lesions.\" This tumor fits that description, making cryotherapy a valid option.\n    *   **Laser Photocoagulation:** This is typically used for smaller, flatter tumors, often after significant chemoreduction. For a tumor of $3$ $\\mathrm{mm}$ thickness, plaque or cryotherapy is generally more suitable.\n    *   **Choice:** Both plaque and cryotherapy are strong candidates. Plaque brachytherapy is very effective for tumors of this thickness and can simultaneously treat the tumor and the contiguous subretinal seeds, fulfilling the role of consolidation. It can be used either after chemoreduction or, for a solitary tumor like this, as a primary definitive treatment.\n\n**Synthesized Composite Plan:**\n*   **RE:** IAC + IViC.\n*   **LE:** A form of chemoreduction followed by or combined with a definitive focal therapy. Plaque brachytherapy is an excellent choice for the focal component given the tumor characteristics.\n*   **Overall:** Avoid EBRT. Prioritize salvage over primary enucleation of the RE.\n\n**Option-by-Option Analysis**\n\n**A. Systemic chemoreduction for both eyes, intravitreal melphalan for the right eye seeds, and laser photocoagulation for the left eye lesion.**\n*   **Right Eye:** Systemic chemoreduction is a suboptimal choice for Group D disease compared to IAC, which offers higher efficacy for eye salvage.\n*   **Left Eye:** Laser photocoagulation is a possible consolidation therapy, but less ideal than plaque or cryotherapy for a tumor with a $3$ $\\mathrm{mm}$ thickness. The principal issue remains the suboptimal approach for the more severely affected right eye.\n*   **Verdict:** **Incorrect**.\n\n**B. Intra-arterial chemotherapy to the right eye with adjunct intravitreal melphalan for vitreous seeds, and plaque brachytherapy to the left eye lesion; avoid External Beam Radiation Therapy.**\n*   **Right Eye:** This plan proposes IAC with adjunct IViC, which is the state-of-the-art, principled approach for salvaging a Group D eye with diffuse vitreous seeds, consistent with our derivation.\n*   **Left Eye:** This plan proposes plaque brachytherapy. The tumor's location ($10$ $\\mathrm{mm}$ from the fovea) and thickness ($3$ $\\mathrm{mm}$) make it a perfect candidate for this modality. Plaque therapy is a definitive focal consolidation treatment.\n*   **Overall:** This plan uses the most effective salvage therapy for the advanced right eye, an excellent and spatially appropriate focal therapy for the left eye, and respects the critical constraint to avoid EBRT. This aligns perfectly with the problem's principles.\n*   **Verdict:** **Correct**.\n\n**C. External Beam Radiation Therapy to both eyes due to posterior involvement and seeding, with deferred focal therapies to minimize immediate anesthesia exposures.**\n*   This plan directly violates the principle of avoiding EBRT in germline patients when alternatives exist. Modern therapies like IAC and IViC are effective alternatives. Deferring therapy for an aggressive cancer like retinoblastoma is also clinically inappropriate.\n*   **Verdict:** **Incorrect**.\n\n**D. Primary enucleation of the right eye given group D status, and plaque brachytherapy for the left eye lesion.**\n*   **Right Eye:** While enucleation is an option for Group D eyes, it contradicts the stated goal of prioritizing eye salvage. A salvage attempt with IAC+IViC is the preferred first step, as prognosis for salvage is reasonable with modern techniques.\n*   **Left Eye:** Plaque brachytherapy is appropriate.\n*   **Overall:** The plan fails by not attempting to salvage the right eye first, which is a primary goal.\n*   **Verdict:** **Incorrect**.\n\n**E. Intravitreal melphalan alone to the right eye without intra-arterial or systemic chemotherapy, and cryotherapy to the left eye lesion without chemoreduction.**\n*   **Right Eye:** IViC alone is critically insufficient. It addresses the vitreous seeds but leaves the main tumor untreated, which will lead to progression and eye loss.\n*   **Left Eye:** The principles state that subretinal seeds respond to \"chemoreduction when coupled with focal consolidation.\" This plan omits the chemoreduction step. While cryotherapy is a valid focal therapy for the location, the lack of a chemoreduction component makes the plan incomplete according to the stated base principles.\n*   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once a chemotherapy regimen is selected, precision in its administration is critical to maximizing efficacy while minimizing toxicity. This final practice provides hands-on experience with a fundamental task in pediatric oncology: calculating a drug dose based on Body Surface Area (BSA). You will apply the standard Mosteller formula to determine the correct vincristine dose for a child, reinforcing the importance of accurate calculations in daily clinical practice. ",
            "id": "5199667",
            "problem": "A $14$-month-old child with unilateral retinoblastoma is scheduled to receive vincristine on Day $1$ of a standard multi-agent chemotherapy cycle. In pediatric oncology, dosing for cytotoxic agents is conventionally normalized to Body Surface Area (BSA) to account for metabolic capacity and drug distribution scaling with size. Use the established Mosteller approximation for Body Surface Area (BSA), $$BSA=\\sqrt{\\frac{h\\cdot w}{3600}},$$ where $h$ is the body length in centimeters and $w$ is the body mass in kilograms. The vincristine dose is specified as $1.5\\ \\text{mg}/\\text{m}^{2}$.\n\nGiven measured anthropometrics $h=86\\ \\text{cm}$ and $w=12.8\\ \\text{kg}$, compute:\n1. The Body Surface Area (BSA) in $\\text{m}^{2}$.\n2. The resulting absolute vincristine dose in $\\text{mg}$.\n\nRound the BSA to four significant figures and the vincristine dose to three significant figures. Express the BSA in square meters and the dose in milligrams. Provide your final answer as a two-entry row matrix with the first entry equal to the BSA and the second entry equal to the dose, following the specified significant-figure rules.",
            "solution": "The problem statement is a well-defined computational task in the field of pediatric pharmacokinetics. It requires the calculation of Body Surface Area (BSA) and a corresponding drug dose based on provided anthropometric data and a standard formula.\n\nFirst, a validation of the problem statement is performed.\n\n**Step 1: Extract Givens**\n- Patient: $14$-month-old child with unilateral retinoblastoma.\n- Drug: Vincristine.\n- Dosing schedule: Day $1$ of a chemotherapy cycle.\n- Dosing normalization parameter: Body Surface Area (BSA).\n- BSA formula (Mosteller approximation): $BSA=\\sqrt{\\frac{h\\cdot w}{3600}}$, where $BSA$ is in $\\text{m}^2$, $h$ is height in $\\text{cm}$, and $w$ is weight in $\\text{kg}$.\n- Vincristine dose rate: $D_{rate} = 1.5\\ \\text{mg}/\\text{m}^{2}$.\n- Patient height: $h=86\\ \\text{cm}$.\n- Patient weight: $w=12.8\\ \\text{kg}$.\n- Required calculations:\n  1. BSA in $\\text{m}^{2}$, rounded to four significant figures.\n  2. Absolute vincristine dose in $\\text{mg}$, rounded to three significant figures.\n- Final answer format: A two-entry row matrix containing the calculated BSA and dose.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The use of BSA for chemotherapy dosing is a standard of care in oncology, particularly in pediatrics. The Mosteller formula is one of the most widely used and validated methods for estimating BSA. The specified drug, dose, and patient characteristics are consistent with established clinical practice for treating retinoblastoma.\n- **Well-Posedness**: The problem provides all necessary data ($h$, $w$), a clear formula for BSA, and a specific dosing rate. The objectives are explicitly stated, and a unique solution can be determined through direct computation.\n- **Objectivity**: The language is precise and quantitative, free of any subjective or ambiguous terms.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Part 1: Calculation of Body Surface Area (BSA)**\nThe Body Surface Area is calculated using the provided Mosteller formula:\n$$BSA = \\sqrt{\\frac{h \\cdot w}{3600}}$$\nThe given values for the patient's height and weight are $h = 86\\ \\text{cm}$ and $w = 12.8\\ \\text{kg}$. Substituting these values into the formula yields:\n$$BSA = \\sqrt{\\frac{86 \\cdot 12.8}{3600}}$$\nFirst, we compute the product in the numerator:\n$$86 \\cdot 12.8 = 1100.8$$\nNow, the expression for BSA becomes:\n$$BSA = \\sqrt{\\frac{1100.8}{3600}}$$\nPerforming the division inside the square root:\n$$\\frac{1100.8}{3600} \\approx 0.305777...$$\nTaking the square root of this value gives the BSA in square meters:\n$$BSA = \\sqrt{0.305777...} \\approx 0.55297184...\\ \\text{m}^2$$\nThe problem requires this value to be rounded to four significant figures. The first four significant figures are $5$, $5$, $2$, and $9$. The fifth significant figure is $7$, which is $\\ge 5$, so we round up the fourth digit.\n$$BSA \\approx 0.5530\\ \\text{m}^2$$\nThe trailing zero is significant and must be included.\n\n**Part 2: Calculation of Absolute Vincristine Dose**\nThe prescribed dose rate for vincristine is $D_{rate} = 1.5\\ \\text{mg}/\\text{m}^{2}$. The absolute dose, $D_{abs}$, is the product of the dose rate and the patient's BSA. To maintain precision, the unrounded value of BSA should be used in this intermediate calculation.\n$$D_{abs} = D_{rate} \\times BSA$$\nSubstituting the values:\n$$D_{abs} = 1.5\\ \\frac{\\text{mg}}{\\text{m}^2} \\times 0.55297184...\\ \\text{m}^2$$\n$$D_{abs} \\approx 0.82945776...\\ \\text{mg}$$\nThe problem requires the final dose to be rounded to three significant figures. The first three significant figures are $8$, $2$, and $9$. The fourth significant figure is $4$, which is $< 5$, so we round down (i.e., truncate at the third significant figure).\n$$D_{abs} \\approx 0.829\\ \\text{mg}$$\n\nThe final answer is presented as a two-entry row matrix with the BSA value followed by the dose value, adhering to the specified rounding rules.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.5530 & 0.829 \\end{pmatrix}}$$"
        }
    ]
}